RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Brain Metastases
Interventions: DRUG: berubicin hydrochloride (RTA 744)
Sponsor: Reata, a wholly owned subsidiary of Biogen